Table S3. Change in Fasting Plasma Insulin (µIU/mL) Baseline to Week 12 Endpoint –Per-Protocol Population

	Placebo (N = 56)	MSDC-0160 50 mg (N = 48)	MSDC-0160 100 mg (N = 52)	MSDC-0160 150 mg (N = 47)	Pioglitazone 45 mg (N = 55)
n [1]	56	48	52	47	55
Baseline Mean (SD) [2]	16.27 (10.974)	16.71 (9.631)	14.91 (10.555)	17.88 (13.988)	13.32 (6.081)
Week 12 Endpoint Mean (SD) [3]	14.29 (10.302)	14.64 (9.187)	14.73 (16.014)	12.61 (8.757)	11.12 (8.005)
Change From Baseline					
LS Mean (SE)	-1.79 (1.146)	-1.73 (1.239)	-0.49 (1.190)	-4.50 (1.256)	-3.07 (1.163)
95% CI	(-4.05, 0.47)	(-4.17, 0.71)	(-2.83, 1.86)	(-6.97, -2.03)	(-5.36, -0.78)
Treatment Comparisons					
vs. Placebo					
LS Mean (SE)		0.06 (1.687)	1.30 (1.653)	-2.71 (1.698)	-1.28 (1.635)
95% CI		(-3.26, 3.38)	(-1.95, 4.56)	(-6.06, 0.63)	(-4.50, 1.94)
p-value		0.9725	0.4314	0.1114	0.4328
vs. Pioglitazone					
LS Mean (SE)		1.34 (1.703)	2.59 (1.660)	-1.43 (1.719)	
95% CI		(-2.01, 4.70)	(-0.68, 5.86)	(-4.81, 1.96)	
p-value		0.4311	0.1205	0.4069	

All post-baseline efficacy measurements taken 6 or more (≥6) days after the last dose of study medication were not included.

Least-squares means, standard errors, confidence intervals, and p-values were from linear contrasts of an ANCOVA model with treatment group as a factor and baseline as a covariate.

*Indicates statistical significance at 0.05 level.

1.   n was the number of patients with values at both baseline and endpoint.
2.   Baseline was defined as the measurement at Visit 2. If the Visit 2 measurement was missing, the last valid measurement prior to the first dose of randomized double-blind study medication was used.
3.   Week 12 endpoint was defined as the Visit 6 (Week 12) measurement. If the Visit 6 (Week 12) measurement was missing, the last valid post-baseline measurement during the double-blind treatment period was carried forward as the endpoint measurement.

ANCOVA = analysis of covariance; CI = confidence interval; LS = least squares; SD = standard deviation; SE = standard error; vs. = versus.